Prevention of congenital Chagas through treatment of girls and women of childbearing age

Moscatelli, Guillermo; Moroni, Samanta; García-Bournissen, Facundo; Ballering, Griselda; Bisio, Margarita; Freilij, Héctor; Altcheh, Jaime

doi:10.1590/0074-02760140347

Cited by 81 publications

(83 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Further, the bulk of our sample was under 40, and could therefore still benefit, if seropositive, from timely etiological treatment to prevent future complications from chronic CD. Such treatment also acts as an effective means of eliminating vertical transmission [8,39,40].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Chagas disease awareness and socioeconomic characteristics of Bolivian immigrants living in São Paulo, Brazil

Silva

Wanderley

Forsyth

et al. 2019

Preprint

View full text Add to dashboard Cite

AbstarctIn this study, part of a research project on Chagas disease among residents of Bolivia in São Paulo, we describe socioeconomic characteristics, knowledge about the disease and access to health services. A structured questionnaire was applied to a sample of 472 Bolivian adults (> 18 years) living in São Paulo enrolled in the Barra Funda School Health Center. The median age of participants was 28.5 years, 75.0% from the Bolivian department of La Paz, who were living in São Paulo for an average of 5.8 years.Regarding knowledge about the disease and exposure to certain risk factors, 47.7% indicated familiarity with the vector, 23.9% had seen vinchuca in their homes in Bolivia and 6.4% reported having been bitten by a triatomine. The conditions of living in rural areas in Bolivia or in other department than La Paz, have a relative with illness, high school graduation and have seen or been bitten by a vinchuca were significantly associated with the knowledge of the vector. This study provides a view on migration that has important implications for the distribution of Chagas' disease and access to health care by providing subsidies for proposing public health policies.

show abstract

Section: Discussionmentioning

confidence: 99%

“…A phenomenon which has received less attention is regional transnational migration within Latin America, its impact on CD epidemiology, and the implications for public health strategies. For instance, some research suggests Bolivian migrants in Buenos Aires may represent a group with higher risk for CD [8].…”

Section: Introductionmentioning

confidence: 99%

Chagas disease awareness and socioeconomic characteristics of Bolivian immigrants living in São Paulo, Brazil

Silva

Wanderley

Forsyth

et al. 2019

Preprint

View full text Add to dashboard Cite

show abstract

“…The benefi ts of an etiological treatment for Chagas disease, such as high percentage of parasitic cure, prevention of disease progression due to a decreased parasitic load (7) (8) (9) , and primary inhibition or interruption of congenital transmission (10) , have been broadly documented in the literature. One of the main barriers for the widespread use of BZN is the high reported incidence of adverse drug reactions (ADRs), documented in up to 50% of treated patients (11) .…”

Section: Discussionmentioning

confidence: 99%

High seroconversion rates in Trypanosoma cruzi chronic infection treated with benznidazole in people under 16 years in Guatemala

Brum-Soares¹,

Cubides²,

Burgos³

et al. 2016

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Introduction: Geographical, epidemiological, and environmental differences associated with therapeutic response to Chagas etiological treatment have been previously discussed. This study describes high seroconversion rates 72 months after benznidazole treatment in patients under 16 years from a project implemented by Doctors without Borders in Guatemala. Methods: An enzyme-linked immunosorbent assay was used to detect Trypanosoma cruzi IgG antibodies in capillary blood samples from patients 72 months after treatment. Fisher's exact test was used to establish association between characteristics, such as sex, age, and origin of patients, and fi nal seroconversion. Kappa index determined concordance between laboratory tests. The level of signifi cance was set to 5%. Results: Ninety-eight patients, aged 6 months to 16 years, were available for follow-up. Sex and origin were not associated with seroconversion. Individuals older than 13 were more prone to maintain a positive result 72 months after treatment, although results were not highly signifi cant. Laboratory tests presented elevated Kappa concordance (95% CI) = 0.8290 (0.4955-1), as well as high (97%) seroconversion rates. Conclusions: The high seroconversion rate found in this study emphasizes the importance of access to diagnosis, treatment, and follow-up of individuals affected by Chagas disease. Moreover, it contradicts the idea that it is not possible to achieve a cure with the currently available drugs. This study strongly supports expanding programs for patients infected with T. cruzi in endemic and non-endemic countries.

show abstract

“…Years after the acute phase, 30%-40% of those infected develop severe complications, usually cardiomyopathy (7). Antitrypanosomal treatment with benznidazole or nifurtimox can halt or delay the onset of cardiomyopathy due to CD (8,9), prevent future congenital transmission (10)(11)(12), and achieve sustained parasite clearance (13). However, this treatment, at least when administered according to current guidelines, has not proven effective in patients who have already developed CD cardiomyopathy (14), making it essential to treat patients while they are still in the asymptomatic phase of the disease.…”

mentioning

confidence: 99%

Increasing access to comprehensive care for Chagas disease: development of a patient-centered model in Colombia

Marchiol¹,

Forsyth²,

Bernal³

et al. 2017

Rev Panam Salud Publica

View full text Add to dashboard Cite

et al. Increasing access to comprehensive care for Chagas disease: development of a patient-centered model in Colombia. Rev Panam Salud Publica. 2017;41:e153. doi: 10.26633/RPSP.2017.153 Worldwide, over 6 million people are infected with Trypanosoma cruzi, the protozoan that causes Chagas disease (CD), yet fewer than 1% of them receive treatment. In Colombia, CD poses a major public health challenge. An estimated 437 000 Colombians are infected with T. cruzi, of whom 131 000 suffer from cardiomyopathy due to the advancement of the disease (1). CD also creates a heavy economic burden; the estimated annual cost of treating a patient in the chronic stage of the disease was US$ 1 028 in 2004 (equivalent to US$ 1 336 in 2017) (2). This entails a total annual cost of US$ 175 016 000 (2017 dollars) for Colombia's health system.CD is most often transmitted by insects of the triatomine subfamily, also known as kissing bugs or, in Colombia, pitos. However, CD can also spread via

show abstract

Prevention of congenital Chagas through treatment of girls and women of childbearing age

Cited by 81 publications

References 9 publications

Chagas disease awareness and socioeconomic characteristics of Bolivian immigrants living in São Paulo, Brazil

Chagas disease awareness and socioeconomic characteristics of Bolivian immigrants living in São Paulo, Brazil

High seroconversion rates in Trypanosoma cruzi chronic infection treated with benznidazole in people under 16 years in Guatemala

Increasing access to comprehensive care for Chagas disease: development of a patient-centered model in Colombia

Contact Info

Product

Resources

About